COMMUNIQUÉS West-GlobeNewswire

NICOX : Nombre de droits de vote au 30 novembre 2018

03/12/2018 - 17:46

Nicox SA Société anonyme au capital de 29 715 320 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 décembre 2018, PUBLICATION MENSUELLE DU NOMBRE D' [...]

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

03/12/2018 - 17:30

- Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda ® (Pembrolizumab) in Hodgkin Lymphoma [...]

Ossur Hf : Transactions in relation to share buyback program

03/12/2018 - 17:00

Announcement no. 69/2018 3 December 2018 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)

03/12/2018 - 16:30

– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML Patients Ineligible for Standard Treatment – – Supplemental New Drug Application for Single [...]

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

03/12/2018 - 16:30

Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple Myeloma ALLO-715 Investigational New Drug Application and Initiation of a Phase 1 Trial Planned for 2019 SOUTH SAN FRANCISCO, Calif., Dec. 03, [...]

Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation

03/12/2018 - 16:15

– 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in Ivosidenib-treated Patients with Secondary AML – – 77% CR+CRi/CRp Rate in Enasidenib-treated Patients with De Novo AML and 64% in [...]

GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

03/12/2018 - 16:00

Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric [...]

Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial

03/12/2018 - 15:31

Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation DUBLIN - December 3, 2018 - Medtronic plc (NYSE:MDT) today announced the [...]

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy

03/12/2018 - 15:15

Company changes name to Outlook Therapeutics, Inc.; ticker symbol to “OTLK” Jeff Evanson joins team as Chief Commercial Officer Terry Dagnon joins team as Chief Operating Officer Closed second tranche of private [...]

Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome

03/12/2018 - 15:00

Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful [...]

Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

03/12/2018 - 15:00

Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient [...]

Golden Leaf Holdings favorably restructures deal terms with Tahoe Hydroponics

03/12/2018 - 14:45

PORTLAND, Ore., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around [...]

Eve & Co Provides Update on Phase 2 Expansion

03/12/2018 - 14:40

TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (TSX-V: EVE) (“Eve & Co” or the “Company”) is pleased to provide an update on its 780,000 square foot greenhouse expansion. The construction of [...]

TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs

03/12/2018 - 14:35

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, [...]

Press release: Terveystalo renews its management structure - decision making and service development closer to the customer

03/12/2018 - 14:31

The business environment in health care is experiencing great change. In order to ensure future competitiveness and to better respond to changing customer expectations and future challenges, Terveystalo will restructure [...]

Enochian Biosciences to Present at Biotech Showcase 2019

03/12/2018 - 14:30

LOS ANGELES, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB: ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to [...]

Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer

03/12/2018 - 14:30

-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company [...]

Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy

03/12/2018 - 14:30

Results demonstrate single intravitreal administration of ADVM-022 gene therapy may provide a safe and effective long-term treatment option for wet AMD, potentially decreasing the need for frequent anti-VEGF injections [...]

Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0

03/12/2018 - 14:30

REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of [...]